Clinical Trial Update: ANG1005 in Leptomeningeal Disease From Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for ANG1005 in leptomeningeal disease from breast cancer (leptomeningeal carcinomatosis/metastases).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Breast Cancer
• Leptomeningeal Carcinomatosis
• Leptomeningeal Metastases

Drugs mentioned

• ANG1005 (GRN1005)

Snippet

Sponsor: Angiochem Inc | Conditions: Leptomeningeal Carcinomatosis, Leptomeningeal Metastases | Phase 3 | Status: UNKNOWN